When is off-label off-road?

por de Vries, E G E, Cherny, N I, Voest, E E
Publicado 2019

When is off-label off-road?

por de Vries, E G E, Cherny, N I, Voest, E E
Publicado 2019

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression

por Houthuijzen, J M, Daenen, L G M, Roodhart, J M L, Voest, E E
Publicado 2012

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

por Groenewegen, G, Walraven, M, Vermaat, J, de Gast, B, Witteveen, E, Giles, R, Haanen, J, Voest, E
Publicado 2012

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit

por Mulder, J., Teerenstra, S., van Hennik, P.B., Pasmooij, A.M.G., Stoyanova-Beninska, V., Voest, E.E., de Boer, A.
Publicado 2023

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer

por Molloy, T J, Devriese, L A, Helgason, H H, Bosma, A J, Hauptmann, M, Voest, E E, Schellens, J H M, van't Veer, L J
Publicado 2011

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado 1997

Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells

por te Velde, E A, Reijerkerk, A, Brandsma, D, Vogten, J M, Wu, Y, Kranenburg, O, Voest, E E, Gebbink, M, Borel Rinkes, I H M
Publicado 2005

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer

por Lalisang, R I, Voest, E E, Wils, J A, Nortier, J W, Erdkamp, F L, Hillen, H F, Wals, J, Schouten, H C, Blijham, G H
Publicado 2000

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

por Kerbusch, T, Groenewegen, G, Mathôt, R A A, Herben, V M M, ten Bokkel Huinink, W W, Swart, M, Ambaum, B, Rosing, H, Jansen, S, Voest, E E, Beijnen, J H, Schellens, J H M
Publicado 2004

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a cas...

por van Berge Henegouwen, J. M., van der Wijngaart, H., Zeverijn, L. J., Hoes, L. R., Meertens, M., Huitema, A. D. R., Devriese, L. A., Labots, M., Verheul, H. M. W., Voest, E. E., Gelderblom, H.
Publicado 2022

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study()(...

por Snoeren, Nikol, van Hillegersberg, Richard, Schouten, Sander B., Bergman, Andre M., van Werkhoven, Erikv, Dalesio, Otilia, Tollenaar, Rob A.E.M., Verheul, Henk M., van der Sijp, Joost, Borel Rinkes, Inne H.M., Voest, E.E.
Publicado 2017

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape

por Vis, D. J., Lewin, J., Liao, R. G., Mao, M., Andre, F., Ward, R. L., Calvo, F., Teh, B. T., Camargo, A. A., Knoppers, B. M., Sawyers, C. L., Wessels, L. F. A., Lawler, M., Siu, L. L., Voest, E.
Publicado 2017

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado 2006

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado 2012

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

por Kerklaan, B Milojkovic, Lolkema, M P J, Devriese, L A, Voest, E E, Nol-Boekel, A, Mergui-Roelvink, M, Langenberg, M, Mykulowycz, K, Stoebenau, J, Lane, S, Legenne, P, Wissel, P, Smith, D A, Giantonio, B J, Schellens, J H M, Witteveen, P O
Publicado 2015

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

por Schipper, L.J., Samsom, K.G., Snaebjornsson, P., Battaglia, T., Bosch, L.J.W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A.J., Jacobs, N., Roepman, P., van der Hoeven, J.J.M., Steeghs, N., Vollebergh, M.A., Marchetti, S., Cuppen, E., Meijer, G.A., Voest, E.E., Monkhorst, K.
Publicado 2022

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

por Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Publicado 2014

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

por Ooft, S.N., Weeber, F., Schipper, L., Dijkstra, K.K., McLean, C.M., Kaing, S., van de Haar, J., Prevoo, W., van Werkhoven, E., Snaebjornsson, P., Hoes, L.R., Chalabi, M., van der Velden, D., van Leerdam, M., Boot, H., Grootscholten, C., Huitema, A.D.R., Bloemendal, H.J., Cuppen, E., Voest, E.E.
Publicado 2021